Get the Stockscreener App
2.59
5.82%
-0.16
After Hours:
2.60
0.01
+0.39%
Proqr Therapeutics N V stock is traded at $2.59, with a volume of 503.97K.
It is down -5.82% in the last 24 hours and up +5.71% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.75
Open:
$2.76
24h Volume:
503.97K
Relative Volume:
1.12
Market Cap:
$272.50M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-6.8374
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-9.44%
1M Performance:
+5.71%
6M Performance:
+30.15%
1Y Performance:
-30.56%
1-Day Range:
$2.48
$2.81
1-Week Range:
$2.48
$3.00
52-Week Range:
$1.07
$4.21
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.59 | 289.70M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases - TipRanks
Transcript : ProQR Therapeutics N.V.Shareholder/Analyst Call - MarketScreener
Can ProQR Therapeutics N.V. (0PQ) stock ride next bull market cycleJuly 2025 Price Swings & Reliable Momentum Entry Alerts - newser.com
How ProQR Therapeutics N.V. (0PQ) stock compares with tech leadersJuly 2025 Selloffs & Verified Trade Idea Suggestions - newser.com
Why ProQR Therapeutics N.V. is moving todayJuly 2025 Gainers & Weekly Sector Rotation Insights - newser.com
Custom watchlist performance reports with ProQR Therapeutics N.V.Weekly Stock Summary & Technical Confirmation Trade Alerts - newser.com
Does ProQR Therapeutics N.V. stock trade at a discount to peers - newser.com
Will ProQR Therapeutics N.V. stock outperform international peersWeekly Risk Summary & AI Powered Market Trend Analysis - newser.com
Will ProQR Therapeutics N.V. stock gain from government policiesMarket Volume Report & Stock Timing and Entry Methods - newser.com
Using Bollinger Bands to evaluate ProQR Therapeutics N.V.July 2025 Big Picture & Step-by-Step Swing Trade Plans - newser.com
Earnings visualization tools for ProQR Therapeutics N.V.2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 80.2% in October - Defense World
Is ProQR Therapeutics N.V. stock attractive for growth ETFsMarket Movers & Weekly Consistent Profit Watchlists - newser.com
Is ProQR Therapeutics N.V. stock cheap at current valuationJuly 2025 Momentum & Low Risk High Reward Trade Ideas - newser.com
Is ProQR Therapeutics N.V. stock a good choice for value investorsTrade Risk Report & Safe Entry Point Identification - newser.com
Why analysts recommend ProQR Therapeutics N.V. (0PQ) stockQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
What catalysts could drive ProQR Therapeutics N.V. stock higherWeekly Loss Report & Consistent Return Strategy Ideas - newser.com
Key metrics from ProQR Therapeutics N.V.’s quarterly dataMarket Risk Summary & Safe Swing Trade Setup Alerts - newser.com
How sentiment analysis helps forecast ProQR Therapeutics N.V.2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Update - MarketBeat
What’s the recovery path for long term holders of ProQR Therapeutics N.V.July 2025 Snapshot & Daily Profit Focused Screening - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Visualizing ProQR Therapeutics N.V. stock with heatmapsTrade Entry Summary & Long Hold Capital Preservation Tips - newser.com
ProQR Therapeutics NV expected to post a loss of 10 cents a shareEarnings Preview - TradingView
ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Is ProQR Therapeutics N.V. (0PQ) stock at risk of policy regulation2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):